XenoPort, Inc.

XenoPort, Inc.

Pharmaceutical Manufacturing 113 employees
Employees
113
Contacts
1
Emails
1
Phones
1

XenoPort, Inc. Overview

Phone Number
Available in AeroLeads
Website
xenoport.com
Industry
Pharmaceutical Manufacturing
Employees
113
Founded
1999
Funding
20.0M
Company Email
Available in AeroLeads
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing

About XenoPort, Inc.

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

XenoPort, Inc. Contact Details

People in AeroLeads
2
With contact data
1
Email contacts
1
50.0% coverage
Phone contacts
1
50.0% coverage

XenoPort, Inc. Org Chart

Sample employees and titles
Name Title Contact
Rajini Rajanna
Email Phone
David R. Savello, Ph.d.
View

Employees by Management Level

Individual contributor 12 profiles
Director 10 profiles
Manager 10 profiles
Executive 2 profiles
Senior / Lead 1 profile

Department Contact Coverage

Department Contacts Email Phone
Executive 7 7 2
General 5 5 2
Sales 4 3 1
IT 2 2 0
Healthcare 2 2 0
Operations 1 1 0

XenoPort, Inc. Tech Stack

Cloud / infrastructure 1 profile
Engineering 1 profile

Compare Similar Companies to XenoPort, Inc.